AVBP · ArriVent BioPharma Inc
United States · RS rating 7 · As of 2026-10-14
| Price | 16.20 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 3 / 5 / 25 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 16 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -9.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +53.4% |
| Market cap (USD) | $1.4B |